Table 2 Peripheral eosinophil reduction post therapy initiation
Measure | Mepolizumab (n = 36) | Benralizumab (n = 19) | p-value |
|---|---|---|---|
Pre-therapy serum eosinophil count, cells/µL, mean (SD) | 597.2 (504.5) | 521.6 (546.8) | 0.3769 |
Patients with pre-therapy eosinophilia (≥ 500 cells/µL) | 0.2730 | ||
Yes, n (%) | 21 (58) | 8 (42) | |
No, n (%) | 15 (42) | 11 (58) | |
Post-therapy serum eosinophil count, cells/µL, mean (SD) | 103.1 (100.0) | 0 (0) | − |
Decrease in serum eosinophil count, cells/µL, mean (SD) | 494.1 (492.9) | 521.6 (546.8) | 0.9079 |
Patients with undetectable eosinophil count post-therapy | < 0.0001 | ||
Yes, n (%) | 11 (31) | 19 (100) | |
No, n (%) | 25 (69) | 0 (0) | |
Patients with pre-therapy eosinophilia (≥ 500 cells/µL) who have normal eosinophil counts (< 500 cells/µL) post-therapy | - | ||
Yes, n (%) | 21 (100) | 8 (100) | |
No, n (%) | 0 (0) | 0 (0) | |
Time from therapy onset to post-therapy serum eosinophil count, days, mean (SD) | 280.4 (191.9) | 118.7 (62.2) | 0.0066 |